Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype
Shoichiro Nakao, Chihaya Kodama, Toshihiro Takenaka, Akihiro Tanaka, Yuichiro Yasumoto, Aichi Yoshida, Tamotsu Kanzaki, Annette L D Enriquez, Christine M Eng, Hiromitsu Tanaka, Chuwa Tei, Robert J Desnick, Shoichiro Nakao, Chihaya Kodama, Toshihiro Takenaka, Akihiro Tanaka, Yuichiro Yasumoto, Aichi Yoshida, Tamotsu Kanzaki, Annette L D Enriquez, Christine M Eng, Hiromitsu Tanaka, Chuwa Tei, Robert J Desnick
Abstract
Background: Fabry disease is an X-linked recessive lysosomal storage disease resulting from deficient alpha-galactosidase A (alpha-Gal A) activity. Renal failure is a major debilitating complication in classically affected males. To determine if this disorder is underdiagnosed in patients with end-stage renal disease (ESRD), the frequency of unrecognized males with Fabry disease on chronic hemodialysis was determined.
Methods: Plasma alpha-Gal A activity was measured in 514 consecutive males with ESRD on hemodialysis. Patients with low alpha-Gal A activity were evaluated clinically and their alpha-Gal A mutations were determined.
Results: Six (1.2%) of 514 hemodialysis patients had low plasma alpha-Gal A activities and a previously identified (E66Q, A97V, M296I) or novel (G373D) missense mutation. At ages 30 to 68 years, five patients lacked the classic manifestations of angiokeratoma, acroparesthesias, hypohidrosis, and ocular opacities, while the sixth lacked angiokeratoma and ocular changes. Five had left ventricular hypertrophy (LVH).
Conclusion: The clinical spectrum of Fabry disease includes a "renal variant" phenotype in patients without classic symptoms who develop ESRD. Affected males undergoing hemodialysis or renal transplantation can be readily diagnosed by plasma alpha-Gal A assays. These patients and their family members may benefit from enzyme replacement therapy for the later, life-threatening cardiovascular and cerebrovascular complications of Fabry disease.
Source: PubMed